Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $89.06M | $-53.41M | $-1.46 |
| 2024 | $65.44M | $-40.45M | $-1.13 |
| 2023 | $45.23M | $-29.46M | $-1.26 |
| 2022 | $25.92M | $-37.16M | $-1.59 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.50 per share
Typical surprise +5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.51 vs $-0.47miss
- Mon, May 11$-0.52 vs $-0.39miss
- Tue, Feb 24$-0.36 vs $-0.43beat
- Tue, Nov 4$-0.37 vs $-0.43beat
- Tue, Aug 5$-0.38 vs $-0.40beat
- Thu, May 8$-0.36 vs $-0.43beat
Estimates and results for CBLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CBLLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (5)
- Newsmarketbeat.com·3d ago·Neutral
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·4d ago·Neutral
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·4d ago·Negative
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
View source ↗